M&A / Deals Sandoz targets industry patent void with $322m Henlius deal Pharmaceutical TechnologySandoz and Henlius will collaborate on up to 10 biosimilars amid opportunity to capitalise on global biosimilar loss-of-exclusivities.Read full story pharminent August 17, 2026 (Last updated: August 18, 2026) Pharmaceutical Technology Sandoz and Henlius will collaborate on up to 10 biosimilars amid opportunity to capitalise on global biosimilar loss-of-exclusivities. Read full story Post navigation Previous: Lantheus Holdings’ Alzheimer’s radiodiagnostic secures FDA approvalNext: Novo Nordisk and AWS form AI partnership to speed drug discovery Related Stories M&A / Deals Solstice Oncology secures $225m to drive porustobart’s development for cancer pharminent September 10, 2026 M&A / Deals UK’s Claret Capital raises 575m for European biotechs pharminent September 7, 2026 M&A / Deals GSK wagers up to $1.3B on a different kind of cancer drug pharminent September 3, 2026